Belite Bio Inc (BLTE)
BLTE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$151.87
-4.24% on the day
Market cap
$6.1B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BLTE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001889109 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-02 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-08 |
Source: SEC EDGAR submissions feed, 210 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.7% |
| 1 month | -10.4% |
| 3 months | +0.7% |
| Year to date | -5.1% |
| 1 year | +90.3% |
| From 52-week high | -21.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International plc | $78.53 | -0.90% | $6.1B |
| LGND | Ligand Pharmaceuticals Incorporated | $303.53 | -2.44% | $6.1B |
| RYTM | Rhythm Pharmaceuticals Inc. | $86.61 | -3.57% | $6.0B |
| ALKS | Alkermes plc | $39.73 | -1.32% | $6.7B |
| PRAX | Praxis Precision Medicines Inc. | $243.34 | -3.20% | $6.8B |
| AMRX | Amneal Pharmaceuticals Inc. | $19.57 | -2.30% | $6.8B |
| IONS | Ionis Pharmaceuticals Inc. | $42.38 | -2.95% | $7.0B |
| SYRE | Spyre Therapeutics Inc. | $80.45 | -6.34% | $7.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier